Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Trial
Official title:
Efficacy and Safety of Toripalimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Phase II Trial (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities. Previous trials have demonstrated that CRT with oral S-1 was tolerable and provided significant survival benefits over radiotherapy alone in elderly patients with esophageal squamous cell carcinoma (ESCC). However, as high as 54% of patients with elderly ESCC experienced locoregional or distant recurrence after CRT. Therefore, a more effective regimen for older patients is needed. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown substantial clinical benefits in advanced esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in locally advanced esophageal cancer. The aim of this study was to evaluate the efficacy and safety of toripalimab (an anti-PD-1 antibody) after concurrent CRT in elderly patients with locally advanced ESCC.
A total of 140 patients with elderly, unresectable, locally advanced ESCC will be stratified according to age (70-80 vs. ≥80) and TNM stage (I/II vs. III/IV) and randomly assigned (1:1) to receive toripalimab as consolidation therapy for up to 12 months (arm A) or not (arm B) after definitive radiotherapy with concurrent S-1. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05743504 -
Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05520619 -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
|
Phase 2 | |
| Recruiting |
NCT04602013 -
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05522894 -
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
|
Phase 2 | |
| Active, not recruiting |
NCT03914443 -
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06426797 -
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT06342167 -
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05130684 -
Neo-NTP-CRT for Locally Advanced ESCC
|
Phase 2 | |
| Not yet recruiting |
NCT04888403 -
Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03917966 -
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
|
Phase 2 | |
| Not yet recruiting |
NCT06356688 -
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 |